Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,410 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares in the company, valued at $34,264,866.02. This represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total value of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total transaction of $335,091.68.

Natera Price Performance

Shares of NASDAQ NTRA traded down $0.61 during midday trading on Wednesday, hitting $274.58. The company’s stock had a trading volume of 1,128,660 shares, compared to its average volume of 1,104,859. The firm has a market capitalization of $39.32 billion, a price-to-earnings ratio of -168.45 and a beta of 1.51. The business’s fifty day simple moving average is $251.03 and its two-hundred day simple moving average is $222.85. Natera, Inc. has a 1 year low of $135.75 and a 1 year high of $288.04.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Barclays dropped their price target on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, June 24th. Royal Bank Of Canada assumed coverage on Natera in a research note on Thursday, June 11th. They set an “outperform” rating and a $275.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price target on shares of Natera in a research report on Tuesday, May 12th. William Blair began coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Finally, BTIG Research set a $275.00 price objective on Natera and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Hedge Funds Weigh In On Natera

A number of institutional investors and hedge funds have recently modified their holdings of the company. Reflection Asset Management purchased a new stake in Natera during the 4th quarter worth about $29,000. Elevation Wealth Partners LLC acquired a new stake in shares of Natera during the 2nd quarter worth about $30,000. Palladiem LLC purchased a new stake in Natera during the fourth quarter worth approximately $31,000. Horizon Investments LLC purchased a new stake in Natera during the third quarter worth approximately $32,000. Finally, International Assets Investment Management LLC boosted its holdings in Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 97 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.